Arsia Therapeutics Inc. and Biogen Sign a Research Collaboration for the Development of Subcutaneous Biologics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Arsia Therapeutics, Inc., a Cambridge based company, today announced a collaboration with Biogen. Arsia and Biogen will focus on providing meaningful treatment administration improvements for hemophilia patients by enabling subcutaneous versions of treatments that are currently administered via intravenous infusion. The companies will combine expertise to research formulations that could be administered at home through convenient subcutaneous injections. As part of the collaboration, Biogen will also utilize Arsia's patented formulation technology, which has broad based utility for the production of high-concentration subcutaneous dose forms of protein and antibody drugs critical for next-generation biologics. Arsia will receive an upfront payment and could be eligible to receive development, regulatory, launch and sales milestones of up to $100M if multiple products are successfully commercialized. Arsia may also receive royalties on certain products arising from the collaboration.

"Our collaboration with Biogen is notable due to our shared commitment to transforming the patient experience through improved drug delivery," said Amy Schulman, CEO of Arsia. "As biologics increase in importance, formulating them so that they can be used easily and reliably is key. The administration of these compounds is critical to patients, to adherence of the treatment regimens, and to the accessibility of biologic medications. Arsia's proprietary technology makes it possible for patients, caregivers, and physicians to administer treatment far more easily."

"We are looking forward to a close, dynamic, and iterative collaboration with Arsia. This collaboration reflects our dedication to the hemophilia patient experience and our commitment to innovation in the formulation space," said Jorg Thommes, Senior Vice President of Technical Development at Biogen.

Robert Langer, an Institute Professor at MIT, the most cited engineer in history, and co-founder of over 20 biotech start-ups in the fields of drug delivery, tissue engineering, and novel drug development, is a founder of Arsia. Langer founded the company with fellow professor and entrepreneur Alexander Klibanov, Novartis Professor of Chemistry and Bioengineering at MIT, and Alan Crane of Polaris Partners. "The foundational work Arsia technology allows will permit a wide range of effective treatments to reach patients that otherwise would not make it past development due to formulation limitations," said Langer.

The deal is the largest announced to date leveraging Arsia's pioneering work in the area of formulation development of protein pharmaceuticals and monoclonal antibodies.

About Arsia

Arsia Therapeutics, Inc. is a biopharmaceutical company based on a platform technology for protein formulation. Arsia produces high-concentration, low-viscosity drug products, enabling biologics that would otherwise be dosed by intravenous infusion to be administered by subcutaneous injection, or delivered by autoinjector pen or patch pump. To date, Arsia's screening technology and library have been successful in collaborations with over 10 major pharmaceutical and biotechnology companies with demonstrated success in viscosity reduction of drug products including antibodies, fusion proteins, and other biologics. Arsia was founded in 2013 by Robert Langer, Alexander Klibanov, and Alan Crane. The company is venture backed by Polaris Partners. For more information, please visitwww.arsiarx.com.

Contact:
Polaris Partners for Arsia
Emily Mendell, 781-522-6732
[email protected]

 

Suggested Articles

Chief Operating Officer Dan Paterson will lead the company while it looks for a permanent successor with commercial chops.

The job losses are part of Sanofi's pivot away from cardiovascular diseases and toward immuno-oncology drugs and gene therapies.

Parexel is looking to bolster its clinical trial work and compliance by signing a new deal with CluePoints.